Sandbox/v43: Difference between revisions
< Sandbox
Gerald Chi (talk | contribs) (Created page with "==Pathogen-Based Therapy <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''Lancet. 2012;380(9854):1693-702.''<ref name="van de Beek-2012">{{Cite journal | last1 = van de Beek...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 70: | Line 70: | ||
| valign=top | | | valign=top | | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table18" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table18" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Acinetobacter baumannii''}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 86: | Line 85: | ||
|} | |} | ||
|} | |} | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Enterobacteriaceae''}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 102: | Line 100: | ||
|} | |} | ||
|} | |} | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table20" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table20" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''H. influenzae'', β-lactamase Negative}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 116: | Line 113: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 2 g IV q6—8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 2 g IV q6—8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' | ||
|- | |- | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''H. influenzae'', β-lactamase Positive}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 126: | Line 123: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 2 g IV q6—8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 2 g IV q6—8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' | ||
|- | |- | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''H. influenzae'', β-lactamase Negative, Ampicillin Resistant}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 134: | Line 131: | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Alternative Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Alternative Regimen'' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' | ||
|- | |- | ||
|} | |} | ||
|} | |} | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Listeria monocytogenes''}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 158: | Line 154: | ||
|} | |} | ||
|} | |} | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table22" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table22" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''N. meningitidis'', Penicillin MIC <0.1 μg/mL}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 172: | Line 167: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h''''' | ||
|- | |- | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''N. meningitidis'', Penicillin MIC ≥0.1 μg/mL}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 184: | Line 179: | ||
|} | |} | ||
|} | |} | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table23" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table23" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Pseudomonas aeruginosa''}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 208: | Line 202: | ||
|} | |} | ||
|} | |} | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table24" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table24" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus aureus'', Methicillin sensitive}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 222: | Line 215: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <SMALL>(trough 15—20 μg/mL)</SMALL><BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 6 mg/kg IV q24h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <SMALL>(trough 15—20 μg/mL)</SMALL><BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 6 mg/kg IV q24h''''' | ||
|- | |- | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus aureus'', Methicillin resistant}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 242: | Line 235: | ||
|} | |} | ||
|} | |} | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table25" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table25" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Staphylococcus epidermidis''}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 266: | Line 258: | ||
|} | |} | ||
|} | |} | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table26" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table26" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''Streptococcus agalactiae''}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 286: | Line 277: | ||
|} | |} | ||
|} | |} | ||
{| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table27" style=" | {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table27" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style=" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''S. pneumoniae'', Penicillin MIC ≤0.06 μg/mL}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 300: | Line 290: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h''''' | ||
|- | |- | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''S. pneumoniae'', Penicillin MIC ≥0.12 μg/mL, Cefotaxime/Ceftriaxone MIC <1.0 μg/mL}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
Line 310: | Line 300: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h''''' | ||
|- | |- | ||
! style=" | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|''S. pneumoniae'', Penicillin MIC ≥0.12 μg/mL, Cefotaxime/Ceftriaxone MIC ≥1.0 μg/mL}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen'' |
Revision as of 07:14, 26 January 2014
Pathogen-Based Therapy Adapted from Lancet. 2012;380(9854):1693-702.[1] and Clin Infect Dis. 2004;39(9):1267-84.[2]
Bacteria ▸ Acinetobacter baumannii ▸ Enterobacteriaceae ▸ Haemophilus influenzae ▸ Listeria monocytogenes ▸ Neisseria meningitidis ▸ Pseudomonas aeruginosa ▸ Staphylococcus aureus ▸ Staphylococcus epidermidis ▸ Streptococcus agalactiae ▸ Streptococcus pneumoniae |
|
References
- ↑ van de Beek, D.; Brouwer, MC.; Thwaites, GE.; Tunkel, AR. (2012). "Advances in treatment of bacterial meningitis". Lancet. 380 (9854): 1693–702. doi:10.1016/S0140-6736(12)61186-6. PMID 23141618. Unknown parameter
|month=
ignored (help) - ↑ Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al. (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 (9):1267-84. DOI:10.1086/425368 PMID: [1]